Abbott Using Myriad's BRACAnalysis to Stratify Patients for Phase III PARP Inhibitor Breast Cancer Trial

Myriad and Abbott have extended existing Rx/Dx partnership to personalize treatment with veliparib into late-stage studies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.